Organ donation performance in the Netherlands 2005-08; Medical record review in 64 hospitals

Nephrology Dialysis Transplantation

Volumn 25, Issue 6, 2010, Pages 1992-1997

  Jansen, Nichon E ^a   Van Leiden, Hendrik A ^a   Haase Kromwijk, Bernadette J J M ^a   Hoitsma, Andries J ^b  

^a Dutch Transplant Foundation   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Conversion rate; Donor Register; Family refusal; Organ donation performance; Potential organ donors

Indexed keywords

DONOR SELECTION; FAMILY; HEART DEATH; HUMAN; MEDICAL RECORD; MEDICAL RECORD REVIEW; NETHERLANDS; ORGAN DONOR; PRIORITY JOURNAL; REVIEW;

FAMILY; HUMANS; NETHERLANDS; REFUSAL TO PARTICIPATE; REGISTRIES; THIRD-PARTY CONSENT; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 77952974476     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp705     Document Type: Review

References (39)

1. http://www.eurotransplant.nl/files/annual-report (accessed 15 June 2009)
2. Jansen NE, van HA Leiden, Sieber-Rasch MH et al. More potential organ donors than actual donations in 52 intensive-care units in the Netherlands, 2001-2004. Ned Tijdschr Geneeskd 2007 Mar 24; 151: 696-701. Dutch
3. Wight C, Cohen B, Roels L et al. Donor Action: a quality assurance program for intensive care units that increases organ donation. J Intensive Care Med 2000; 15: 104-114
4. http://www.Donorregister.nl/annual report 2007 (assessed 25 April 2009)
5. Annual report 2008 of the Dutch Transplant Foundation. The Netherlands, 2008. Dutch
6. Cuende MN, Canon Campos JF, Serrano Miranda B et al. The organ donation process: a program for its evaluation and improvement. Organs and Tissues 2002; 5: 109-118
7. Sheehy E, Conrad SL, Brigham LE et al. Estimating the number of potential organ donors in the United States. N Engl J Med 2003; Aug 14; 349: 667-674
8. Barber K, Falvey S, Hamilton C et al. Potential for organ donation in the United Kingdom: audit of intensive care records. BMJ 2006; May 13; 332: 124-127
9. Wesslau C, Grosse K, Krüger R et al. How large is the organ donor potential in Germany? Results of an analysis of data collected on deceased with primary and secondary brain damage in intensive care unit from 2002 to 2005. Transpl Int 2007; Feb; 20: 147-155 (Pubitemid 46127367)
10. Roels L, Spaight C, Smits J et al. Donation patterns in four European countries: data from the donor action database. Transplantation 2008; 86: 1738-1743
11. Jansen NE, Haase-Kromwijk BJJM, van Leiden HA et al. A plea for uniform European definitions for donor potential and family refusal rates. Transpl Int 2009; Nov; 22: 1064-1072
12. Roodnat JI, van Riemsdijk IC, Mulder PG et al. The superior results of living-donor renal transplantation are not completely caused by selection or short cold ischemia time: a single-center, multivariate analysis. Transplantation 2003; 75: 2014-2018
13. Siminoff LA, Gordon N, Hewlett J et al. Factors influencing families' consent for donation of solid organs for transplantation. JAMA 2001; 286: 71-77
14. De Jong W, Franz HG, Wolfe SM et al. Requesting organ donation: an interview study of donor and nondonor families. Am J Crit Care 1998; 7: 13-23
15. Blok GA, van Dalen J, Jager KJ et al. The European Donor Hospital Education Programme (EDHEP): addressing the training needs of doctors and nurses who break bad news, care for the bereaved, and request donation. Transpl Int 1999; 12: 161-167
16. Masterplan Organ donation. Report of the Coordination group organ donation. The Netherlands, 2008. Dutch
17. Ha H et al. Nephrol Dial Transpl 2006; 21(Suppl 2): iv33
18. Hills CE, Al-Rasheed N, Al-Rasheed N et al. C-Peptide reverses TGF-{beta}1-induced changes in renal proximal tubular cells: implications for the treatment of diabetic nephropathy. Am J Physiol Renal Physiol 2009; 296: F614-F621
19. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705
20. Kulkarni O, Pawar RD, Purschke W et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007; 18: 2350-2358
21. Li Y, Reddy MA, Miao F et al. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-depen-dent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem 2008; 283: 26771-26781
22. Miao F, Gonzalo IG, Lanting L et al. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 2004; 279: 18091-18097
23. Miao F, Smith DD, Zhang L et al. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 ly-sine 9 dimethylation: an epigenetic study in diabetes. Diabetes 2008; 57: 3189-3198
24. Miao F, Wu X, Zhang L et al. Histone methylation patterns are cell-type specific in human monocytes and lymphocytes and well maintained at core genes. J Immunol 2008; 180: 2264-2269
25. Ninichuk V, Clauss S, Kulkarni O et al. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3′PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 2008; 172: 628-637
26. Ninichuk V, Kulkarni O, Clauss S et al. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy. Eur J Med Res 2007; 12: 351-355
27. Oldfield MD, Bach LA, Forbes JM et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108: 1853-1863
28. Prigent C, Dimitrov S. Phosphorylation of serine 10 in histone H3, what for? J Cell Sci 2003; 116: 3677-3685
29. Qian Y, Feldman E, Pennathur S et al. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 2008; 57: 1439-1445
30. Reddy MA, Villeneuve LM, Wang M et al. Role of the lysine-spe-cific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. Circ Res 2008; 103: 615-623
31. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?. Diabetologia 2008; 51: 714-725
32. Schlondorff D. The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J 1987; 1: 272-281
33. Schmid H, Boucherot A, Yasuda Y et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic ne-phropathy. Diabetes 2006; 55: 2993-3003
34. Tikoo K, Meena RL, Kabra DG et al. Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br J Pharmacol 2008; 153: 1225-1231
35. Villagra A, Cheng F, Wang HW et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009; 10: 92-100
36. Villeneuve LM, Reddy MA, Lanting LL et al. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory pheno-type of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 2008; 105: 9047-9052
37. Wade PA. Transcriptional control at regulatory checkpoints by his-tone deacetylases: molecular connections between cancer and chro-matin. Hum Mol Genet 2001; 10: 693-698
38. Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 2009; 9: 91-105
39. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787